Teva announces availability of bioequivalent to osteoporosis treatment Evista

JERUSALEM — Teva Pharmaceuticals on Tuesday announced the introduction and availability of Raloxifene hydrochloride tablets, USP. This product is AB rated and bioequivalent to Evista tablets.  

Raloxifene hydrochloride tablets, USP are indicated for the treatment and prevention of osteoporosis in postmenopausal women. 

Teva was first to file, making the product eligible for 180 days of marketing exclusivity.

Evista 60 mg Tablets marketed by Eli Lilly and Co., had annual sales of approximately $824 million in the United States, according to IMS data as of December 2013.